All In Biotech

Drug Trial Radar · NCT07858422

A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa

A Phase II Study Evaluating the Safety and Efficacy of ENERGI-F703EB Cream in Subjects With Epidermolysis Bullosa

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 8, 2026

Primary completion

Mar 15, 2027

Study completion Jun 15, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, intra-subject randomized, double-blind, vehicle-controlled, parallel, multicenter study to evaluate the safety and preliminary efficacy of ENERGI-F703EB Cream in subjects who are ≥ 18 years old with epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), or dystrophic epidermolysis bullosa (DEB). In total, approximately 24 subjects will be enrolled from multiple sites in Taiwan. The study duration per subject is approximately 16 weeks; which includes a 2 to 4-week period between Visit 1 and Visit 2 for screening, an 8-week period from Visit 2 to Visit 7 for treatment, and a 4-week period from Visit 7 to Visit 9 for safety follow-up.

Conditions

  • Epidermolysis Bullosa (EB)
  • Junctional Epidermolysis Bullosa
  • Epidermolysis Bullosa Simplex
  • Dystrophic Epidermolysis Bullosa

Interventions

  • ENERGI-F703EB CreamDrug

    Standard of care and ENERGI-F703EB Cream is applied for the treatment of Epidermolysis Bullosa

  • Matched vehicle creamDrug

    Standard of care and matched vehicle cream is applied for the treatment of Epidermolysis Bullosa

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Local Target Lesion Adverse EventsTime frame: Day 1 through Day 85

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.